PL407163A1 - Biomarkery transkryptomiczne, sposób określania i zastosowanie biomarkerów transkryptomicznych do stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolności serca - Google Patents

Biomarkery transkryptomiczne, sposób określania i zastosowanie biomarkerów transkryptomicznych do stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolności serca

Info

Publication number
PL407163A1
PL407163A1 PL407163A PL40716314A PL407163A1 PL 407163 A1 PL407163 A1 PL 407163A1 PL 407163 A PL407163 A PL 407163A PL 40716314 A PL40716314 A PL 40716314A PL 407163 A1 PL407163 A1 PL 407163A1
Authority
PL
Poland
Prior art keywords
transcriptomic biomarkers
heart failure
transcriptomic
biomarkers
post
Prior art date
Application number
PL407163A
Other languages
English (en)
Other versions
PL228091B1 (pl
Inventor
Beata Burzyńska
Monika Góra
Agata Maciejak
Dorota Tułacz
Marek Kiliszek
Marcin Michalak
Grzegorz Opolski
Krzysztof Matlak
Sławomir Dobrzycki
Original Assignee
Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Warszawski Uniwersytet Medyczny
Uniwersytet Medyczny W Białymstoku
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biochemii I Biofizyki Polskiej Akademii Nauk, Warszawski Uniwersytet Medyczny, Uniwersytet Medyczny W Białymstoku filed Critical Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority to PL407163A priority Critical patent/PL228091B1/pl
Priority to EP15712187.2A priority patent/EP3105350B1/en
Priority to PCT/IB2015/000141 priority patent/WO2015121737A2/en
Publication of PL407163A1 publication Critical patent/PL407163A1/pl
Publication of PL228091B1 publication Critical patent/PL228091B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem wynalazku są biomarkery transkryptomiczne do stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolności serca odpowiadające podwyższonemu poziomowi ekspresji co najmniej dwóch genów z grupy transkryptów obejmującej: FNM1, RNASE1, TIMP1, JDP2, lub co najmniej jednego genu z grupy transkryptów obejmującej: FMN1, RNASE1, JDP2.
PL407163A 2014-02-12 2014-02-12 Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro PL228091B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL407163A PL228091B1 (pl) 2014-02-12 2014-02-12 Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro
EP15712187.2A EP3105350B1 (en) 2014-02-12 2015-02-12 Transcriptomic biomarkers, method for determination thereof and use of transcriptomic biomarkers for individual risk assessment of developing post-infarction heart failure
PCT/IB2015/000141 WO2015121737A2 (en) 2014-02-12 2015-02-12 Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL407163A PL228091B1 (pl) 2014-02-12 2014-02-12 Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro

Publications (2)

Publication Number Publication Date
PL407163A1 true PL407163A1 (pl) 2015-08-17
PL228091B1 PL228091B1 (pl) 2018-02-28

Family

ID=52737367

Family Applications (1)

Application Number Title Priority Date Filing Date
PL407163A PL228091B1 (pl) 2014-02-12 2014-02-12 Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro

Country Status (3)

Country Link
EP (1) EP3105350B1 (pl)
PL (1) PL228091B1 (pl)
WO (1) WO2015121737A2 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201902077D0 (en) * 2019-02-14 2019-04-03 Univ College Dublin Nat Univ Ireland Dublin Biomarkers
CN110478484B (zh) * 2019-08-08 2021-10-26 中山大学 抑制jdp2表达的物质在制备抗肿瘤药物中的应用
DE102020205364B4 (de) 2020-04-28 2022-01-20 Universität Rostock Verfahren zur Überwachung des Verlaufs einer Kardiomyozyten-Transplantation und Methode zur Bestimmung, ob ein Proband für einer Kardiomyozyten-Transplantation geeignet ist
CN111593121A (zh) * 2020-07-07 2020-08-28 吉林大学 G0s2基因在急性心肌梗死风险预测标记物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090046825A (ko) * 2006-07-11 2009-05-11 무스크 파운데이션 포 리서치 디벨롭먼트 프로테아제 및 프로테아제 저해제 프로파일링으로 심근 경색 후 심부전을 예측하는 방법
US20110294683A1 (en) * 2008-10-30 2011-12-01 Centre de Recherche Public de la Sant'e Biomarkers
HK1208470A1 (en) * 2012-03-29 2016-03-04 Biogen Ma Inc. Biomarkers for use in integrin therapy applications

Also Published As

Publication number Publication date
WO2015121737A2 (en) 2015-08-20
WO2015121737A3 (en) 2015-11-26
EP3105350B1 (en) 2019-04-10
PL228091B1 (pl) 2018-02-28
WO2015121737A4 (en) 2016-02-04
EP3105350A2 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
JOP20200115A1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
WO2012106718A3 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
EP3362075A4 (en) NATURAL KILLER CELLS AND ILC3 CELLS AND USES THEREOF
BR112014028881A2 (pt) populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células
EP3268494A4 (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
BR112019010565A2 (pt) aplicação viral de neoantígenos
MX375786B (es) Biosintesis microbiana de ergotioneina.
BR112017012142A2 (pt) método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama
EA201692370A1 (ru) КОМПОЗИЦИИ иРНК АНГИОТЕНЗИНОГЕНА (AGT) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
EA201891192A1 (ru) Средства и способы лечения миопатий, связанных с титином, и других титинопатий
EP3280797A4 (en) GENERATION OF FUNCTIONAL CELLS FROM STEM CELLS
BR112016016916A2 (pt) método de tratamento de angiodema hereditário (hae)
EP3324982A4 (en) HEMATOPOIETIC STEM CELLS EXPRESSING PD-L1 AND USES
HUE050579T2 (hu) Eljárás mezenchimális sztómasejt-bank elõállítására több csontvelõdonor egyesített mononukleáris sejtjeibõl
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
EP3286301A4 (en) GENERATION OF DIFFERENTIATION OF MUSCELLINARY CELLS FROM STEM CELLS
EP3798316A3 (en) Genes and gene signatures for diagnosis and treatment of melanoma
CY1123677T1 (el) Απομονωση αυθεντικων παγκρεατικων προγονικων κυτταρων
LT3170896T (lt) Pliuripotentinių kamieninių ląstelių, turinčių antigenui specifinį t ląstelių receptoriaus geną, gavimo būdas
IL259750A (en) Method for determining cell clonality of a cell bank
PL407163A1 (pl) Biomarkery transkryptomiczne, sposób określania i zastosowanie biomarkerów transkryptomicznych do stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolności serca
CL2016003140A1 (es) Sistema de expresión génica
BR112018009097A8 (pt) spodoptera frugiperda resistente a vip3a
LT3724319T (lt) Iš raumenų kilusių ląstelių gavimo būdas
EP3693456A4 (en) PROCESS FOR THE PRODUCTION OF A GENETICALLY VARIOUS T-LYMPHOCYTES COLONY DERIVED FROM AN IPS CELL